• 1
    Rabkin CS. Epidemiology of B-cell lymphomas. Curr Top Microbiol Immunol. 1999; 246: 235239.
  • 2
    Sepkowitz KA. AIDS—the first 20 years. N Engl J Med. 2001; 344: 17641772.
  • 3
    Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: 2730.
  • 4
    Buchbinder SP, Holmberg SD, Scheer S, Colfax G, O'Malley P, Vittinghoff E. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: 2326.
  • 5
    Sparano JA, Anand K, Desai J, Mitnick RJ, Kalkut GE, Hanau LH. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: 1822.
  • 6
    Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: 1117.
  • 7
    Chassagne-Clement C, Blay JY, Treilleux I, et al. [ Epidemiology of non-Hodgkin's lymphoma: recent data]. Bull Cancer. 1999; 86: 529536.
  • 8
    Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001; 98: 23392344.
  • 9
    Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: 3441.
  • 10
    Tirelli U, Errante D, Carbone A, Gloghini A, Vaccher E. Malignant lymphomas in patients with HIV infection. Leuk Lymphoma. 1996; 22: 245257.
  • 11
    Matthews GW, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000; 96: 27302734.
  • 12
    Kaplan LD, Abrams DI, Geigal EU. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989; 261: 719724.
  • 13
    Kaplan L, Kahn J, Northfelt D, Abrams D, Volberding P. Novel combination chemotherapy for Hodgkin's disease (HD) in HIV-infected individuals [abstract]. Proc Am Soc Clin Oncol. 1991; 10: A7.
  • 14
    Tirelli U, Errante D, Oksenhendler E, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognostic AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol. 1992; 3: 843847.
  • 15
    Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med. 1993; 95: 188196.
  • 16
    Remick SC, McSharry JJ, Wolf BC, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol. 1993; 11: 16911702.
  • 17
    Aviles A, Nambo MJ, Halabe J. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen. Ann Hematol. 1999; 10: 452455.
  • 18
    Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336: 16411648.
  • 19
    Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol. 1987; 5: 13221328.
  • 20
    Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996; 14: 30263035.
  • 21
    Campbell P, Iland H, Gibson J, Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. Br J Haematol. 1999; 105: 795798.
  • 22
    Gabarre J, Leblond V, Sutton L, et al. Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma. Bone Marrow Transplant. 1996; 18: 11951197.
  • 23
    Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1989; 111: 973981.
  • 24
    Bouabdallah R, Stoppa AM, Rossi JF, et al. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients. Leukemia. 1999; 13: 950956.
  • 25
    Stoppa AM, Bouabdallah R, Chabannon C, et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognostic non-Hodgkin's lymphoma. J Clin Oncol. 1997; 15: 17221729.
  • 26
    Ratner L, Lee J, Tang SC, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 19: 21712178.
  • 27
    Gordon LI, Harrington D, Anderson J. Comparison of second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992; 327: 13421349.
  • 28
    Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 29
    Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognostic aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1999; 13: 29162923.
  • 30
    Bouabdallah R, Coso D, Costello R, et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow Transplant. 2000; 25: 3540.
  • 31
    Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847858.
  • 32
    Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994; 32: 292300.
  • 33
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 239: 987992.
  • 34
    Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989; 7: 10181026.
  • 35
    Kwak LW, Halpern J, Olshen RA. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963977.
  • 36
    Collins C, Mortimer J, Livingston BB. High-dose cyclophosphamide in the treatment of refractory lymphoma and solid tumor malignancies. Cancer. 1989; 63: 228232.
  • 37
    Takvorian T, Canellos GP, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987; 316: 14991505.
  • 38
    Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 14921499.
  • 39
    Errante D, Vaccher E, Tirelli U. Are hematopoietic colony-stimulating factors useful in association with chemotherapy in the treatment of HIV-related non- Hodgkin's lymphomas? Ann Oncol. 1996; 7: 233237.
  • 40
    Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000; 355: 10711072.
  • 41
    Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS. 2003; 17: 137138.
  • 42
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood. 1998; 92: 19271932.
  • 43
    Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma. 1994; 14: 263271.
  • 44
    Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991; 9: 929940.
  • 45
    Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses. 1999; 15: 619624.
  • 46
    Costello RT, Brunet C, Dignat-George F, Sampol J, Olive D, Gastaut JA. Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. Hematol J. 2002; 3: 216218.